Related by context. All words. (Click for frequent words.) 80 metastatic colorectal cancer 75 mCRC patients 72 KRAS wild 71 metastatic renal cell carcinoma 71 mRCC 70 FOLFIRI 70 advanced NSCLC 69 HER2 positive metastatic breast 69 SCCHN 68 hormone refractory prostate cancer 68 assessing T DM1 68 metastatic CRC 68 Metastatic Colorectal Cancer 67 NSCLC 67 relapsed refractory multiple myeloma 66 Vectibix 66 hepatocellular cancer 66 randomized Phase III 66 phase IIb clinical 65 docetaxel chemotherapy 65 renal cell carcinoma 65 cancer mCRC 64 sunitinib 64 metastatic melanoma 64 refractory metastatic colorectal cancer 64 metastatic castration resistant 64 B CLL 64 HRPC 64 TORISEL 64 gemcitabine 64 FOLFOX4 64 gemcitabine chemotherapy 64 axitinib 64 gefitinib 63 Amrubicin 63 vandetanib 63 recurrent NSCLC 63 carboplatin paclitaxel 63 leukemia CLL 63 lymphoma CTCL 63 sorafenib 63 KRAS status 63 chronic lymphocytic leukemia CLL 63 cetuximab 63 cetuximab Erbitux ® 63 AVASTIN 63 metastatic renal cell 63 Irinotecan 63 free survival PFS 63 adecatumumab 63 Brentuximab Vedotin SGN 63 metastatic GIST 62 cell lymphoma CTCL 62 castration resistant prostate cancer 62 plus dexamethasone 62 sorafenib Nexavar ® 62 chemotherapy regimens 62 FOLFOX 62 cutaneous T cell 62 docetaxel 62 sunitinib malate 62 dacarbazine 62 unresectable 62 dasatinib Sprycel ® 62 pancreatic adenocarcinoma 62 non squamous NSCLC 62 metastatic RCC 62 bevacizumab Avastin ® 62 sorafenib Nexavar 62 bevacizumab Avastin 62 IMA# 62 refractory multiple myeloma 62 refractory AML 62 ® cetuximab 62 Phase Ib II 62 cetuximab Erbitux R 62 glufosfamide 62 chlorambucil 62 BRIM3 61 capecitabine 61 erlotinib Tarceva ® 61 pegylated liposomal doxorubicin 61 superficial bladder cancer 61 Taxotere R 61 eculizumab 61 panitumumab 61 hepatocellular carcinoma HCC 61 metastatic carcinoma 61 FOLFIRI chemotherapy 61 soft tissue sarcoma 61 follicular lymphoma FL 61 metastatic castrate resistant 61 indolent NHL 61 erlotinib 61 EGFR expressing mCRC 61 bevacizumab 61 Phase 1b 61 Pemetrexed 61 oral ridaforolimus 61 chronic myeloid leukemia CML 61 Taxotere ® 61 Phase Ib study 61 bendamustine 61 IV NSCLC 61 malignant pleural mesothelioma 61 decitabine 61 elacytarabine 61 LUX Lung 61 refractory NSCLC 61 HER2 + 61 nab paclitaxel 61 recurrent glioblastoma multiforme 61 recurrent GBM 61 afatinib 61 enzastaurin 61 mapatumumab 61 FOLOTYN 61 multiple myeloma MM 61 evaluating T DM1 61 KRAS mutations occur 61 Myelodysplastic Syndrome MDS 61 temsirolimus 61 registrational trial 61 Phase Ib 61 trastuzumab 60 Aflibercept 60 refractory chronic lymphocytic 60 familial amyloidotic polyneuropathy FAP 60 perifosine 60 prostate cancer HRPC 60 recurrent glioblastoma 60 stage IIIB 60 FOLFOX6 60 Fludara 60 metastatic breast cancer 60 OncoVEX GM CSF 60 platinum refractory 60 irinotecan containing 60 HER2 positive 60 Torisel 60 relapsed multiple myeloma 60 pemetrexed 60 bortezomib 60 prostate cancer CRPC 60 MabCampath 60 K ras 60 HER2 positive breast cancer 60 TMC# C# 60 refractory CTCL 60 unresectable locally advanced 60 SCH # 60 HGS ETR1 60 type KRAS 60 gefitinib Iressa 60 irinotecan 60 Metastatic Renal Cell Carcinoma 60 metastatic hormone refractory 60 Aplidin 60 Dacogen injection 60 Multiple Myeloma MM 60 Proxinium TM 60 tamibarotene 60 TYKERB 60 trabectedin 60 chemoradiotherapy 60 Clolar ® 60 gastrointestinal stromal tumor GIST 60 pegylated interferon alpha 60 neoadjuvant chemotherapy 60 Cloretazine ® 60 non metastatic osteosarcoma 60 IMPACT IMmunotherapy 60 HuMax CD4 60 metastatic pancreatic cancer 60 Fludara ® 60 Trastuzumab 60 alvespimycin 60 posaconazole 59 pertuzumab 59 standard chemotherapy regimens 59 TEMODAL 59 glioblastoma multiforme GBM 59 bevacizumab Avastin R 59 crizotinib PF # 59 BRIM2 59 acute coronary syndromes ACS 59 Hepatocellular Carcinoma HCC 59 colorectal liver metastases 59 histone deacetylase HDAC inhibitor 59 dose escalation trial 59 IRESSA 59 recurrent glioma 59 Folfox 59 plus prednisone 59 Bevacizumab 59 dasatinib 59 metastatic HRPC 59 telaprevir dosed 59 standard chemotherapy regimen 59 hepatocellular carcinoma 59 IMGN# 59 depsipeptide 59 mTOR inhibitor 59 plus gemcitabine 59 K RAS 59 Phase Ib clinical 59 ELACYT 59 pomalidomide 59 dose escalation Phase 59 Velcade bortezomib 59 infusional 5-FU/LV 59 relapsing multiple sclerosis 59 IV metastatic melanoma 59 Phase 2b clinical 59 metastatic colon cancer 59 invasive aspergillosis 59 metastatic malignant 59 SUTENT 59 advanced unresectable 59 Randomized Phase 59 receptor tyrosine kinase inhibitor 59 EFAPROXYN 59 relapsed MM 59 GW# [003] 59 HCV SPRINT 59 advanced hepatocellular carcinoma 59 tanespimycin 59 CIMZIA ™ 59 FOLFIRI alone 59 invasive candidiasis 59 Phase #/#a trial 59 XELOX 59 AEG# 59 imatinib therapy 59 fluoropyrimidine 59 leukemia AML 59 5 fluorouracil 59 CANCIDAS 59 PEGINTRON TM 59 Gemzar ® 59 Castration Resistant Prostate Cancer 59 XL# SAR# 59 myelodysplastic syndrome MDS 59 castrate resistant prostate cancer 59 low dose cytarabine 59 Phase IIb clinical 59 multicentre randomized 59 relapsed CLL 59 Phase 1b clinical 59 Annamycin 59 Xelox 59 tesmilifene 59 CR# vcMMAE 59 aflibercept VEGF Trap 58 metastatic colorectal carcinoma 58 gemcitabine Gemzar ® 58 antibody MAb 58 Tamibarotene 58 Targretin 58 FOLFOX chemotherapy 58 Follicular Lymphoma 58 metastatic malignant melanoma 58 PXD# 58 Phase 2a clinical 58 azacitidine 58 acute myeloid leukemia AML 58 Acute Myeloid Leukemia AML 58 ongoing Phase 1b 58 RG# [001] 58 elotuzumab 58 ERBITUX 58 dirucotide 58 Cloretazine 58 metastatic colorectal 58 docetaxel Taxotere R 58 blinatumomab 58 idarubicin 58 biologic therapy 58 evaluating tivozanib 58 metastatic CRPC 58 Azedra 58 cetuximab Erbitux 58 EGFR TKI 58 unresectable stage 58 palifosfamide 58 PROVENGE ® 58 FOLOTYN ® 58 RE LY 58 cancer neuroendocrine tumor 58 OPAXIO 58 factor receptor EGFR 58 Ozarelix 58 EGFR mutation 58 pharmacokinetic PK study 58 cediranib 58 follicular NHL 58 metastatic pancreatic 58 aflibercept 58 leukemia ALL 58 Ranolazine 58 relapsed refractory 58 KRAS mutant tumors 58 solid tumors 58 gemcitabine carboplatin 58 Halaven 58 follicular lymphoma 58 PROSTVAC TM 58 lintuzumab 58 Phase IIa clinical 58 trastuzumab Herceptin R 58 ribavirin RBV 58 phase IIa clinical 58 VELCADE melphalan 58 MYDICAR ® 58 soft tissue sarcomas 58 phase IIb study 58 Myelofibrosis 58 CBLC# 58 Prostate AdenoCarcinoma Treatment 58 evaluating Prochymal 58 Doxil ® 58 T#I [002] 58 BR.# 58 imatinib resistant 58 Epratuzumab 58 TTF Therapy 58 Nexavar sorafenib 58 gastric cancer 58 chemotherapeutic regimen 58 relapsing remitting multiple sclerosis 58 Newly Diagnosed Multiple Myeloma 58 TRANSFORMS 58 imetelstat 58 Alocrest 58 opioid induced constipation OIC 58 brain metastases 58 Avastin bevacizumab 58 cutaneous T 58 capecitabine Xeloda R 58 tocilizumab 58 gastrointestinal stromal tumors GIST 58 thymalfasin 58 Bortezomib 58 Imprime PGG 58 adalimumab 58 Temsirolimus 58 Quinamed 58 fluoropyrimidine oxaliplatin 58 refractory cutaneous T 57 BCIRG 57 YONDELIS 57 TACE 57 FTY# 57 aHUS 57 Peginterferon 57 seliciclib 57 ZACTIMA 57 Phase 2b study 57 Capecitabine 57 Chronic Hepatitis C 57 Hormone Refractory Prostate Cancer 57 terlipressin 57 SPRYCEL ® 57 Phase IIIb clinical 57 PEGylated interferon beta 1a 57 liver metastases 57 phase IIb trial 57 TRISENOX 57 gemcitabine Gemzar 57 amrubicin 57 randomized controlled Phase 57 vinorelbine 57 Phase #b/#a clinical 57 TheraSphere 57 pralatrexate 57 T#I mutation 57 carboplatin 57 belinostat 57 unique alkylating agent 57 doxorubicin HCl liposome injection 57 Aplidin R 57 elagolix 57 Advanced Renal Cell 57 Voreloxin 57 davunetide intranasal AL 57 trastuzumab Herceptin ® 57 INCB# [001] 57 HCV RESPOND 2 57 pancreatic NET 57 Chronic Lymphocytic Leukemia 57 lymphoid malignancies 57 Glufosfamide 57 docetaxel Taxotere ® 57 irinotecan chemotherapy 57 carcinoid tumors 57 satraplatin Phase 57 Gemcitabine 57 idiopathic pulmonary fibrosis IPF 57 thalidomide Thalomid 57 interferon gamma 1b 57 lupus nephritis 57 oxaliplatin 57 myelodysplastic syndromes MDS 57 CD3 monoclonal antibody 57 pharmacokinetic PK 57 EGFR mutations 57 cilengitide 57 stage IIIb IV 57 hematologic malignancies 57 Phase 2b trial 57 acute leukemias 57 galiximab 57 chemotherapeutic agent 57 Phase 2a trial 57 diagnosed multiple myeloma 57 cytarabine 57 T DM1 57 pulmonary arterial hypertension PAH 57 CYT# potent vascular disrupting 57 locoregional 57 acute promyelocytic leukemia APL 57 Acute Myelogenous Leukemia AML 57 5 fluorouracil leucovorin 57 sorafenib tablets 57 systemic lupus erythematosus 57 carfilzomib 57 Phase 1b trial 57 5FU 57 resistant ovarian cancer 57 refractory gout 57 TELCYTA 57 CIMZIA TM 57 biliary tract cancer 57 Pivotal Phase III 57 KRAS 57 DAPT 57 non squamous 57 diabetic nephropathy 57 multicenter Phase 57 Vicinium TM 57 docetaxel Taxotere 57 alkylating agent 57 AVOREN 57 dose escalation clinical 57 Soft Tissue Sarcoma 57 ACTEMRA TM 57 peginterferon alfa 2a 57 symptomatic BPH 57 BIBW 57 NMIBC 57 acute ischemic stroke 57 AVADO 57 EGFR HER2 57 immunotherapeutic agent 57 PKC# 57 acute HAE attacks 57 recurrent malignant glioma 57 ADVANCE PD 57 temozolomide 57 5-FU/LV 57 imatinib 57 ADVEXIN 57 Sorafenib 57 Pralatrexate 57 PREZISTA r 57 Vectibix monotherapy 57 CALGB # [001] 57 paclitaxel Taxol 57 Pegasys ® 57 Ambrisentan 57 Meets Primary Endpoint 56 forodesine 56 dose escalation study 56 Genasense ® 56 Phase IIa trial 56 monotherapy 56 medullary thyroid cancer 56 myeloproliferative disorders 56 APPRAISE 56 fludarabine 56 BARACLUDE ® 56 imatinib Gleevec ® 56 rituximab 56 tumors GIST 56 temsirolimus Torisel ® 56 Free Survival PFS 56 recurrent ovarian cancer 56 Ceplene/IL-2 56 rNAPc2 56 sapacitabine 56 HGS ETR2 56 topotecan 56 naïve HCV 56 micafungin 56 PegIntron 56 Cutaneous T 56 nonsmall cell lung cancer 56 CA4P 56 FOLFOX regimen 56 VELCADE 56 prospective multicenter 56 interferon alfa 2a 56 CALGB # [002] 56 Hodgkin lymphoma NHL 56 COU AA 56 chemotherapy regimen 56 sipuleucel T 56 Traficet EN 56 ofatumumab HuMax CD# 56 trabedersen 56 paclitaxel carboplatin 56 lumiliximab 56 Actimmune ® 56 NXL# 56 ofatumumab 56 systemic anaplastic large 56 capecitabine Xeloda 56 PDX pralatrexate 56 etoposide 56 Sym# 56 CIMZIA TM certolizumab pegol 56 chemoradiation 56 bone metastasis 56 basal cell carcinoma BCC 56 IgG1 monoclonal antibody 56 virologic response 56 Hepatocellular Carcinoma 56 luteinizing hormone releasing 56 Erbitux cetuximab 56 romidepsin 56 lesinurad 56 metastatic NSCLC 56 follicular non 56 pain palliation 56 IFN α 56 ganetespib 56 Ceflatonin 56 p# biomarker 56 Lenalidomide 56 KRAS gene 56 prospectively defined 56 Triapine 56 TO AVOID PREGNANCY WHILE 56 Erlotinib 56 anti EGFR antibody 56 PEG interferon 56 placebo controlled clinical 56 ELOXATIN 56 zalutumumab 56 Fludarabine 56 MGd 56 nilotinib 56 gastrointestinal stromal tumors 56 Alemtuzumab 56 myelodysplastic syndromes 56 multicenter randomized placebo controlled 56 metastatic SCCHN 56 EGFR expressing 56 adjuvant radiation 56 ILLUMINATE 56 imatinib Gleevec 56 fosbretabulin 56 oblimersen 56 Mylotarg 56 Phase III randomized controlled 56 randomized Phase 56 prostate cancer mCRPC 56 iniparib 56 ASA# 56 Omacetaxine 56 androgen independent 56 phase IIb 56 INTELENCE 56 resminostat 56 romiplostim 56 intravenous belinostat 56 Epoetin alfa 56 PegIFN 56 Glioblastoma Multiforme 56 bucindolol 56 daunorubicin 56 randomized multicenter Phase III 56 cisplatin 56 Pixantrone 56 CHOP chemotherapy 56 Xanafide 56 velafermin 56 Tavocept 56 cell lung cancer 56 anticancer agent 56 CLL 56 Dasatinib 56 neoadjuvant treatment 56 EDEMA3 56 Azixa 56 fallopian tube carcinoma 56 phase Ib 56 thromboembolic events 56 tyrosine kinase inhibitors 56 primary hypercholesterolemia 56 evaluating picoplatin 56 ROCKET AF 56 pegylated interferon 56 ABVD 56 regorafenib 56 L MTP PE 56 doxorubicin docetaxel 56 CMV disease 56 FOLPI 56 anticancer compound 56 ToGA 56 GvHD 56 brivaracetam 56 Neoadjuvant 56 heavily pretreated 56 Renal Cell Carcinoma RCC 56 Tarceva TM 56 neoadjuvant therapy 56 panobinostat 56 5 FU leucovorin 56 HGS# 56 rALLy 56 IL# PE#QQR 56 EOquin TM 56 viral kinetic 56 chemoradiation therapy 56 pegylated interferon alfa 2a 56 Metastatic Melanoma 56 Pharmacokinetics PK 56 metastatic gastric 56 Renal Cell Carcinoma 56 relapsed SCLC 56 Eculizumab 56 Acute Myeloid Leukemia 56 Cell Lung Cancer 56 Pivotal Trial 56 PSMA ADC 56 dacarbazine DTIC 56 Ph + ALL 56 radiation sensitizer 56 PROSTVAC ® 56 Ixempra 56 BRAF mutation 56 plus DOXIL 56 Carfilzomib 56 HuMax EGFr 56 neuroendocrine tumors 56 alvimopan 56 prostate cancer AIPC 55 sorafenib Nexavar R 55 nitazoxanide 55 melphalan prednisone 55 Oral Fingolimod 55 Ceflatonin R 55 Perifosine 55 confirmatory Phase III 55 alfa 2a 55 Ranibizumab 55 Nexavar ® 55 Dacogen decitabine 55 hematological malignancies 55 RoACTEMRA 55 pazopanib 55 evaluating Xcytrin 55 SUCCEED trial 55 severe oral mucositis 55 Pirfenidone 55 VIDAZA 55 Gleevec resistant 55 Genasense 55 Amigal 55 Navelbine 55 zanolimumab 55 liposomal amphotericin B 55 recurrent colorectal cancer 55 indolent follicular non 55 Vandetanib 55 novel histone deacetylase 55 relapsed GBM 55 atypical Hemolytic Uremic Syndrome 55 chronic myelogenous leukemia CML 55 AQ4N 55 Acute Ischemic Stroke 55 stage IIIb 55 deforolimus 55 registrational 55 vidofludimus 55 ZOLINZA 55 XL# [003] 55 Solid Tumors 55 Phase 1a 55 MT#/MEDI-# 55 abiraterone acetate 55 hematological cancers 55 essential thrombocythemia 55 relapsing remitting MS RRMS 55 AA amyloidosis 55 inhibitor RG# 55 bortezomib Velcade 55 Catena ® 55 FOLFOX6 chemotherapy regimen 55 ORENCIA ® 55 EGFr 55 squamous 55 dose cohorts 55 Phase III randomized 55 EGFR mutation positive 55 docetaxel prednisone 55 mycophenolate mofetil 55 PRE SURGE 55 metaglidasen 55 Camptosar ® 55 OMAPRO 55 obatoclax 55 ATTR 55 gastrointestinal stromal tumor 55 Tarceva erlotinib 55 VICTRELIS 55 Degarelix 55 clofarabine 55 adult chronic ITP 55 Sapacitabine 55 adriamycin 55 STRIDE PD 55 IRX 2 55 EGFR tyrosine kinase inhibitors 55 pancreatic carcinoma 55 Metastatic 55 BiTE antibody MT# 55 trastuzumab DM1 T DM1 55 vorinostat 55 CLL8 55 Relapsed Refractory 55 Ceftaroline 55 Troxatyl 55 Navelbine ® 55 Augment Injectable 55 refractory Hodgkin lymphoma 55 refractory prostate cancer 55 randomized Phase IIb 55 Folotyn 55 Tesetaxel 55 Neulasta ® 55 Myelodysplastic Syndrome 55 Malignant Melanoma 55 MEND CABG 55 figitumumab 55 proteasome inhibitor 55 acute myelogenous leukemia AML 55 Diabetic Macular Edema 55 CD# monoclonal antibody 55 Pivotal Phase 55 glatiramer acetate 55 Nexavar tablets 55 GVAX 55 Randomized Phase II 55 tyrosine kinase inhibitor 55 virus HCV protease inhibitor 55 GISTs 55 Clolar 55 APTIVUS 55 Telaprevir 55 MEK inhibitor 55 GOUT 55 sunitinib Sutent ® 55 hormone receptor positive 55 Myelodysplastic Syndromes 55 Severe Sepsis 55 Diffuse Large B 55 ALN TTR# 55 adjuvant therapy 55 Hedgehog Pathway Inhibitor 55 CEQ# 55 lapatinib Tykerb 55 peginterferon alfa 2b 55 myelofibrosis polycythemia vera 55 IIa trial 55 peginterferon 55 ara C 55 glioblastoma 55 bosutinib 55 APTIVUS r 55 rFVIIa 55 INCB# [002] 55 Xcytrin 55 generation Hsp# inhibitor 55 teriflunomide 55 metastatic neuroendocrine tumors 55 cisplatin gemcitabine 55 Carboplatin 55 tiotropium 55 ZYBRESTAT 55 CML CP 55 humanized anti 55 prostate cancer PCa 55 ATL# [001] 55 REVLIMID ® 55 R sorafenib tablets 55 dose cohort 55 carcinoma mCRC 55 tolvaptan 55 xanthine oxidase inhibitor 55 JAK inhibitor 55 IV melanoma 55 SHPT 55 neurogenic orthostatic hypotension 55 EORTC 55 FLT3 55 mitoxantrone 55 neratinib 55 vascular disrupting agent 55 EGFR inhibitors 55 severe sepsis 55 NOXAFIL 55 taxane chemotherapy 55 ADXS# 55 Betaferon ® 55 trastuzumab emtansine T DM1 55 Plicera 55 DOXIL 55 immunomodulatory therapy 55 Kit CD# positive 55 bleomycin 55 Hsp# Inhibitor 55 Amplimexon 55 BEXXAR Therapeutic Regimen 55 Panitumumab 55 virological response 55 5 FU 55 RDEA# 55 antitumor activity 55 phase IIa 55 Panzem R NCD 55 advanced nonsquamous NSCLC 55 cangrelor 55 cell acute lymphoblastic 55 vemurafenib 55 ixabepilone 55 nucleoside analog 55 HCD# [002] 55 HBeAg negative patients 55 tesetaxel 55 bosentan 55 ceftaroline 55 Romiplostim 55 transthyretin TTR mediated amyloidosis 55 bortezomib Velcade ® 55 relapsing remitting MS 55 REVLIMID lenalidomide 55 cisplatin chemotherapy 55 boosted protease inhibitor 55 unresectable Stage III 55 remission induction 55 colorectal cancer liver metastases 55 5-fluorouracil/leucovorin 55 xenograft models 55 PRECiSE 55 nilotinib Tasigna ® 55 Exelixis XL# 55 Onrigin 55 taxane 55 metastatic prostate cancer 55 Phenoptin 55 R lenalidomide 55 efalizumab 55 trastuzumab Herceptin 55 systemic ALCL 55 VFEND 55 OXi# 54 K ras mutations 54 PI3K/Akt pathway inhibitor 54 SVR# 54 Val HeFT 54 HSCT 54 Bosutinib 54 EGFR expressing metastatic colorectal 54 fallopian tube cancers 54 Phase 2a 54 Alkeran 54 Philadelphia Chromosome Positive 54 Lenocta 54 lenalidomide Revlimid R 54 Nilotinib 54 Hodgkin lymphoma HL 54 panitumumab Vectibix 54 GIST 54 epithelial tumors 54 TG# [001] 54 Chronic Lymphocytic Leukemia CLL 54 ON #.Na 54 maribavir 54 TREANDA 54 PEGINTRON 54 relapsed AML 54 investigational humanized monoclonal antibody 54 Haptoglobin 54 CD# antibody [001] 54 CYT# 54 ocular formulation 54 Androxal TM 54 INCB# [003] 54 Phase IIIb 54 Advexin 54 Revlimid 54 hepatitis C HCV 54 Gleevec Glivec 54 Ofatumumab 54 Adalimumab 54 eltrombopag 54 CAELYX 54 pan HDAC inhibitor 54 lamivudine 54 fluorouracil 54 HNSCC 54 Xeloda capecitabine 54 Cetuximab 54 XIENCE V PROMUS Stent 54 bortezomib Velcade R 54 PD LID 54 Elitek 54 situ CIS 54 advanced carcinoid 54 TG MV 54 colorectal cancer CRC 54 Phase III clinical 54 KRAS mutation 54 pivotal Phase III 54 goserelin 54 entecavir 54 Vascugel ® 54 neurologic progression 54 nucleoside analogue 54 atherothrombotic events 54 Jevtana 54 omacetaxine mepesuccinate 54 XGEVA 54 Neuradiab 54 Boceprevir 54 HDAC Inhibitor 54 Phase III Clinical Trial 54 registrational Phase 54 MyVax R 54 AEGR 54 gastric adenocarcinoma 54 Nexavar 54 PROVENGE sipuleucel T 54 CCX# 54 Allovectin 7 54 AVONEX ® 54 plus ribavirin 54 Cell Lymphoma 54 hepatoma 54 tenofovir emtricitabine 54 APEX AMI trial 54 secondary hyperparathyroidism 54 investigational compound 54 ASCO GI 54 hypercalcemia 54 Telatinib 54 PRT# 54 painful diabetic neuropathy 54 AP# [003] 54 BCR ABL inhibitor 54 RAV# 54 AA Amyloidosis 54 TMC# [001] 54 resectable 54 pan histone deacetylase 54 ritonavir boosted 54 imatinib mesylate Gleevec 54 Apaziquone 54 refractory indolent non 54 dasatinib Sprycel 54 Sprycel dasatinib 54 ovarian carcinoma 54 Tanespimycin 54 Cloretazine R VNP#M 54 Phase #b/#a 54 Chronic Myeloid Leukemia 54 colorectal cancer mCRC 54 entinostat 54 neoadjuvant 54 Clofarabine 54 TACI Ig 54 MEK inhibitor RDEA# 54 relapsed ovarian cancer 54 valopicitabine 54 rilonacept 54 Natalizumab 54 recurrent metastatic 54 BRAF inhibitor 54 leading oral taxane 54 initiate Phase 1b 54 differentiated thyroid 54 voreloxin 54 myelofibrosis 54 chronic myeloid 54 celgosivir 54 Fibrin Pad